The most common AEs of any grade in anti-PD-1/PD-L1 in combination therapy were fatigue (28%-87%), nausea (39%-79.7%), diarrhea (28.3%-56.5%), alopecia (33%-92.4%), and anemia (28.3%-94.6%). This evidence concerns the gene PDCD1 and anemia (phenotype).